Boris V. Nikonenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Boris V. Nikonenko has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Carol A. Nacy
Sequella, Inc., Rockville, Maryland, USA
6 shared publicationsLeo Einck
Sequella, Inc., Rockville, Maryland, USA
6 shared publicationsMarina Protopopova
Sequella, Inc., Rockville, Maryland, USA
3 shared publicationsElena Bogatcheva
Sequella, Inc., Rockville, Maryland, USA
2 shared publicationsRowena Samala
Sequella, Inc., Rockville, Maryland 20850,1 Central Research Institute for Tuberculosis, Moscow 107564, Russia2
2 shared publicationsVenkata M. Reddy
Sequella, Inc., Rockville, Maryland, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2014
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (1) , 587-589
Therapeutic Efficacy of SQ641-NE against Mycobacterium tuberculosis
A phospholipid-based nanoemulsion formulation of SQ641 (SQ641-NE) was active against intracellular Mycobacterium tuberculosis in J774A.1 mouse macrophages, although SQ641 by itself was not. Intravenous (i.v.) SQ641-NE was cleared from circulation and reached peak concentrations in lung and spleen in 1 h. In a murine tuberculosis (TB) model, 8 i.v. doses of SQ641-NE at 100 mg/kg of body weight over 4 weeks caused a 1.73 log 10 CFU reduction of M. tuberculosis in spleen and were generally bacteriostatic in lungs.
- 1 January 2014
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (1) , 587-589
Open AccessTherapeutic Efficacy of SQ641-NE against Mycobacterium tuberculosis
A phospholipid-based nanoemulsion formulation of SQ641 (SQ641-NE) was active against intracellular Mycobacterium tuberculosis in J774A.1 mouse macrophages, although SQ641 by itself was not. Intravenous (i.v.) SQ641-NE was cleared from circulation and reached peak concentrations in lung and spleen in 1 h. In a murine tuberculosis (TB) model, 8 i.v. doses of SQ641-NE at 100 mg/kg of body weight over 4 weeks caused a 1.73 log 10 CFU reduction of M. tuberculosis in spleen and were generally bacteriostatic in lungs.
- 1 May 2013
- Published by Elsevier in Tuberculosis
- Vol. 93 (3) , 285-290
Drug testing in mouse models of tuberculosis and nontuberculous mycobacterial infections
- 1 May 2013
- Published by Elsevier in Tuberculosis
- Vol. 93 (3) , 285-290
Drug testing in mouse models of tuberculosis and nontuberculous mycobacterial infections
- 1 October 2010
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 10 (7) , 1151-1154
Anti-tuberculosis drug therapy in mice of different inbred strains
- 1 October 2010
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 10 (7) , 1151-1154
Anti-tuberculosis drug therapy in mice of different inbred strains
- 1 July 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (7) , 3138-3139
Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis
New delivery vehicles and routes of delivery were developed for the capuramycin analogue SQ641. While this compound has remarkable in vitro potency against Mycobacterium tuberculosis , it has low solubility in water and poor intracellular activity. We demonstrate here that SQ641 dissolved in the water-soluble vitamin E analogue α-tocopheryl polyethylene glycol 1000 succinate (TPGS) or incorporated into TPGS-micelles has significant activity in a mouse model of tuberculosis.
- 1 July 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (7) , 3138-3139
Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis
New delivery vehicles and routes of delivery were developed for the capuramycin analogue SQ641. While this compound has remarkable in vitro potency against Mycobacterium tuberculosis , it has low solubility in water and poor intracellular activity. We demonstrate here that SQ641 dissolved in the water-soluble vitamin E analogue α-tocopheryl polyethylene glycol 1000 succinate (TPGS) or incorporated into TPGS-micelles has significant activity in a mouse model of tuberculosis.
- 1 June 2008
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Infective Drug Discovery
- Vol. 3 (2) , 102-116
Preclinical Study of New TB Drugs and Drug Combinations in Mouse Models
Tuberculosis (TB) remains one of the leading infectious killers in the world. New anti-TB drugs and more effective drug combinations are urgently needed, particularly given the increasing incidence of drug-resistant TB and HIV-TB co-infection. This review describes the available mouse models of TB and describes their utility in the evaluation of new TB drug candidates and in the evaluation of the efficacy of new TB drug combinations. Some of the most recent patents on promising TB drug-candidates are also mentioned here.
- 1 June 2008
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Infective Drug Discovery
- Vol. 3 (2) , 102-116
Preclinical Study of New TB Drugs and Drug Combinations in Mouse Models
Tuberculosis (TB) remains one of the leading infectious killers in the world. New anti-TB drugs and more effective drug combinations are urgently needed, particularly given the increasing incidence of drug-resistant TB and HIV-TB co-infection. This review describes the available mouse models of TB and describes their utility in the evaluation of new TB drug candidates and in the evaluation of the efficacy of new TB drug combinations. Some of the most recent patents on promising TB drug-candidates are also mentioned here.
- 1 April 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (4) , 1563-1565
Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs
Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log 10 lower in SQ109-containing regimens.
- 1 April 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (4) , 1563-1565
Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs
Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log 10 lower in SQ109-containing regimens.
- 1 December 2004
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (12) , 4550-4555
Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis
We evaluated the use of a simple and easy-to-obtain potential marker of tuberculosis (TB) drug efficacy, body weight, and correlated weight loss or gain with the number of CFU of Mycobacterium tuberculosis in lungs and spleens of infected mice. C3H mice were infected intravenously with 10 6 CFU of virulent M. tuberculosis H37Rv, and body weight was evaluated for several weeks after infection. At day 20, infected untreated mice consistently lost more than 25% of their body weight. Chemotherapy with selected orally active anti-TB drugs was initiated 7 days following infection and continued for 13 days. Drugs that were administered daily by gavage included isoniazid (INH), ethambutol (EMB), rifampin (RIF), and moxifloxacin (MXF). At the most effective doses, each of these drugs inhibited bacterial growth and abolished infection-induced body weight loss. Chemotherapy with 1/10 the standard dose of INH determined in accepted long-term murine models of TB also prevented body weight loss, while chemotherapy with 1/10 the standard dose of RIF did not. With only 2 weeks of chemotherapy, we observed a good reverse correlation between CFU in lung or spleen and body weight of mice. The simple measurement of weight in TB-infected drug-treated mice required only a weight balance, and go/no-go drug efficacy data was available on day 20 without the necessity of prolonged drug treatment and long (3 weeks or more) in vitro culture times to obtain organ CFU values.
- 1 December 2004
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (12) , 4550-4555
Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis
We evaluated the use of a simple and easy-to-obtain potential marker of tuberculosis (TB) drug efficacy, body weight, and correlated weight loss or gain with the number of CFU of Mycobacterium tuberculosis in lungs and spleens of infected mice. C3H mice were infected intravenously with 10 6 CFU of virulent M. tuberculosis H37Rv, and body weight was evaluated for several weeks after infection. At day 20, infected untreated mice consistently lost more than 25% of their body weight. Chemotherapy with selected orally active anti-TB drugs was initiated 7 days following infection and continued for 13 days. Drugs that were administered daily by gavage included isoniazid (INH), ethambutol (EMB), rifampin (RIF), and moxifloxacin (MXF). At the most effective doses, each of these drugs inhibited bacterial growth and abolished infection-induced body weight loss. Chemotherapy with 1/10 the standard dose of INH determined in accepted long-term murine models of TB also prevented body weight loss, while chemotherapy with 1/10 the standard dose of RIF did not. With only 2 weeks of chemotherapy, we observed a good reverse correlation between CFU in lung or spleen and body weight of mice. The simple measurement of weight in TB-infected drug-treated mice required only a weight balance, and go/no-go drug efficacy data was available on day 20 without the necessity of prolonged drug treatment and long (3 weeks or more) in vitro culture times to obtain organ CFU values.